Product
tNIV 1 and Matrix-M Adjuvant
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of AgeStatus: Not yet recruiting, Estimated PCD: 2025-05-23